Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Nsclc
• Age: Between 18 Year(s) - 99 Year(s)
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1. Has surgically resected (R0) and histologically confirmed diagnosis of Stage II, IIIA, IIIB (with nodal involvement [N2]) squamous or nonsquamous NSCLC
  2. Confirmation that EGFR-directed therapy is not indicated as primary therapy (historical documentation of absence of tumor-activating EGFR mutations [eg, DEL19 or L858R] or as determined by either a local or the central laboratory)
  3. Has received at least one dose of adjuvant treatment with standard of care platinum doublet chemotherapy up to 4 cycles

  
  

You may not be eligible for this study if the following are true:

• 1. Diagnosis of SCLC or, for mixed tumors, presence of small cell elements, or has a neuroendocrine tumor with large cell components or a sarcomatoid carcinoma
  2. HIV-infected participants with a history of Kaposi’s sarcoma and/or Multicentric Castleman’s Disease
  3. Received prior neoadjuvant therapy for their current NSCLC diagnosis